Ruth Illingworth

The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models

I. Barrett, K. Varnäs, K. Valerie, 2018, Science Advances.

Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.

G. Basarab, A. Eakin, P. Boriack-Sjodin, 2013, Journal of medicinal chemistry.

Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099).

G. Basarab, A. Eakin, C. Garner, 2014, Journal of medicinal chemistry.

Pyrrolamide DNA Gyrase Inhibitors: Fragment-Based Nuclear Magnetic Resonance Screening To Identify Antibacterial Agents

Ning Gao, Haihong Ni, Oluyinka Green, 2011, Antimicrobial Agents and Chemotherapy.